New York-Men bothered by overactive bladder and prostate enlargement symptoms who are treated simultaneously with the anticholinergic drug tolterodine tartrate extended-release capsules (Detrol LA) and the alpha-blocker tamsulosin (Flomax) report better symptom control and quality of life than do men treated with either one of the medications or placebo, according to a recently published study (JAMA 2006; 296:2319-28).
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.